NEWS


Controlled Release of Liothyronine (LT3) Shown in First Clinical Trial of PolyZincLiothyronine (PZL)

Synthonics, Inc., a specialty pharmaceutical company focused on the development of proprietary metal coordinated pharmaceuticals, today announced the results of the first clinical trial of…MORE

Synthonics to Begin Clinical Trial of Extended Release T3

Synthonics, Inc., a specialty pharmaceutical company focused on the development of proprietary metal coordinated pharmaceuticals, today announced the approval of the Phase 1 clinical trial of…MORE

Sustained Release T3 Therapy: Animal Models and Translational Applications

The standard of care to treat hypothyroidism is daily administration of levo-thyroxine (LT4). This is based on the understanding that deiodinases can restore production of T3 and…MORE